ADHD Drugs Show Promise for Menopausal Brain Fog in Early Trials
A scoping review finds ADHD medications lisdexamfetamine and atomoxetine significantly improved self-reported executive function in perimenopausal women, though objective cognitive test scores did not change. Researchers highlight the need for larger trials to confirm efficacy and safety for this unapproved use.
ADHD medications may alleviate the subjective experience of menopausal brain fog, according to a new review of early trials. Two small crossover studies showed the drugs lisdexamfetamine and atomoxetine were associated with significant improvements in self-reported executive function in perimenopausal women aged 45 to 60.
Women taking either medication reported greater improvements on the Brown Attention Deficit Disorder Scale (BADDS) compared to those receiving a placebo. The review found an estimated 44 to 60 percent of perimenopausal women report cognitive changes like forgetfulness and difficulty concentrating. No medication is currently approved by the US Food and Drug Administration specifically for treating menopausal brain fog.
Subjective Improvements Noted
The analysis of two randomized controlled trials revealed clear improvements in how women felt about their cognitive function. In the studies, women's self-rated symptoms on the BADDS scale dropped significantly when they were on active medication versus placebo.
| Drug | Baseline BADDS Score | Score on Drug | Score on Placebo | P-value |
|---|---|---|---|---|
| Lisdexamfetamine | 35.7 | 21.2 | 29.8 | <0.001 |
| Atomoxetine | 38.6 | 25.5 | 30.1 | 0.009 |
Pallavi Khanna said: "Both drugs improved how women rated their executive function, but not their scores on objective cognitive tests."
Limited Objective Impact
Despite the positive self-reports, the ADHD medications did not show significant improvements on standardized objective cognitive tests. Neither lisdexamfetamine nor atomoxetine led to significant gains on most objective measures, which included assessments of working memory and sustained attention. This disconnect between subjective experience and objective performance highlights a key area for further investigation.
Mechanistic Rationale
Researchers propose a biological basis for testing ADHD drugs for this purpose. Declining and fluctuating oestrogen levels during the menopause transition affect chemical signalling in the brain, including pathways for dopamine and norepinephrine that are involved in attention and cognitive function. These neurochemical changes can contribute to symptoms resembling ADHD, such as difficulties with working memory, attention, and processing speed. JoAnn E. Manson noted, "There may be overlap in vulnerability to ADHD and to menopausal cognitive symptoms such as brain fog." The review also found that more severe ADHD symptoms were associated with a greater burden of perimenopausal symptoms.
Key Limitations and Cautions
The evidence remains preliminary, constrained by several important factors. All the randomized controlled trials came from a single research group and excluded women with prior ADHD diagnoses. The review did not include any studies of methylphenidate, another common ADHD medication, or comparisons with hormone therapy, a standard treatment for other menopausal symptoms. For most women, brain fog at menopause is a temporary condition that does not lead to permanent cognitive changes or dementia. However, it can last long enough to disrupt work and daily routines and cause significant stress and anxiety. That is why researchers say studies like this are important in helping to identify additional options for symptoms. The evidence about whether having a formal ADHD diagnosis affects physical and psychological menopause symptoms was inconsistent. Larger and more diverse trials are needed to confirm efficacy and safety before any clinical adoption for this purpose.
